Ditching cannabis growing tech for hemp-based drinks marks a new era for the firm under its new GTI leadership.

The CBD maker said state-level changes in hemp laws as public health concerns rise are impeding attempts to expand its retail ...

Unpack the industry with the daily cannabis newsletter for business leaders.

The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

While broader real estate stocks rallied on the Federal Reserve’s latest rate cut, with the Real Estate Select Sector SPDR ...

The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

A new credit facility provided $8 million in net proceeds for growth initiatives ahead of a planned mid-2025 integration with ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...